Virus therapy takes on Drug-Resistant colorectal cancer

NCT ID NCT01380600

Completed Disease control Sponsor: Jennerex Biotherapeutics Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This early-phase trial tests a modified virus called JX-594 (Pexa-Vec) in people with advanced colorectal cancer that has not responded to standard treatments. The virus is designed to infect and kill cancer cells while also stimulating the immune system. The main goal is to check the safety of giving this virus by intravenous infusion every two weeks, and to find the highest dose that can be given safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JX-594 (a modified vaccinia virus with GM-CSF)
What this could lead to: If it works, this could point toward a new treatment option for advanced colorectal cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase safety study with only 15 participants, so it is too small to prove effectiveness. The virus therapy may cause serious side effects, including flu-like symptoms and other toxicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates